Health care utilization (HCU) by breast cancer (BC) and non-Hodgkin lymphoma (NHL) patients (pts) with chemotherapy (CT) induced febrile neutropenia (FN) in the Netherlands

被引：0
|
作者：
Gelderblom, Hans
Lugtenburg, Pieternella
Nortier, J. W. R.
van Herk-Sukel, Myrthe
Issa, Djamila
Jager, A.
De La Orden, Margarita
van der Werf-Langenberg, Mirte
Houweling, Leanne
De Jong, Floris Aart
机构：
[1] Leiden Univ, Dept Clin Oncol, Med Ctr, Leiden, Netherlands
[2] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands
[3] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands
[5] Erasmus Univ, Dept Med Oncol, Med Ctr, Daniel den Hoed Canc Ctr, Rotterdam, Netherlands
[6] Amgen Int, Ctr Observat Res, Uxbridge, Middx, England
[7] Amgen BV, Med Dept Oncol & Hematol, Breda, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16526
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin's Lymphoma
    Engert, Andreas
    del Giglio, Auro
    Bias, Peter
    Lubenau, Heinz
    Gatzemeier, Ulrich
    Heigener, David
    ONKOLOGIE, 2009, 32 (10): : 599 - 604
  • [32] A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
    Lyman, Gary H.
    Mezzio, Dylan
    Li, Edward C.
    Campbell, Kim
    Balu, Sanjeev
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [33] Evaluation of Relative Dose Intensity (RDI) by Age in Patients (pts) with Non-Hodgkin Lymphoma (NHL) Receiving Pegfilgrastim and CHOP Based Chemotherapy
    Balducci, Lodovico
    Mo, May
    Abella, Steve
    Saven, Alan
    BLOOD, 2012, 120 (21)
  • [34] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma
    Intragumtornchai, T
    Sutheesophon, J
    Sutcharitchan, P
    Swasdikul, D
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 351 - 360
  • [35] CLINICAL CONSEQUENCES OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY
    Ozer-Deniz, S.
    Taylor, D. C.
    Hill, G.
    Skornicki, M.
    Danel, A.
    Kunz, E.
    VALUE IN HEALTH, 2010, 13 (07) : A253 - A253
  • [36] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of chop chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
    Intragumtornchai, T
    Sutheesophon, J
    Sutcharitjan, P
    Swasdikul, D
    BLOOD, 1998, 92 (10) : 225B - 225B
  • [37] History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis
    Chao, Chun
    Rodriguez, Roberto
    Page, John H.
    Yang, Su-Jau
    Huynh, Julie
    Chia, Victoria M.
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 72 - 79
  • [38] Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system
    Wen, Tsun-Jen
    Wen, Yu-Wen
    Chien, Chun-Ru
    Chiang, Shao-Chin
    Hsu, William Wei-Yuan
    Shen, Li-Jiuan
    Hsiao, Fei-Yuan
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2017, 23 (02) : 288 - 293
  • [39] Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2)
    Yokoyama, Masahiro
    Kusano, Yoshiharu
    Nishihara, Anna
    Inoue, Norihito
    Nishimura, Noriko
    Mishima, Yuko
    Terui, Yasuhito
    Nukada, Tomoyuki
    Nomura, Takanobu
    Hatake, Kiyohiko
    SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 571 - 579
  • [40] Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2)
    Masahiro Yokoyama
    Yoshiharu Kusano
    Anna Nishihara
    Norihito Inoue
    Noriko Nishimura
    Yuko Mishima
    Yasuhito Terui
    Tomoyuki Nukada
    Takanobu Nomura
    Kiyohiko Hatake
    Supportive Care in Cancer, 2020, 28 : 571 - 579
12345